ifosfamide has been researched along with Carcinoma, Thymic in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "From October 1995 to April 2001, 18 patients with advanced thymoma or thymic carcinoma were entered on trial, and receive etoposide (100 mg/m(2) on days 1-3), ifosfamide (1500 mg/m(2) on days 1-3), s and cisplatin (30 mg/m(2) on days 1-3)." | 9.14 | Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. ( André, M; Bretel, JJ; Caliandro, R; Grassin, F; Le Chevalier, T; Margery, J; Paleiron, N; Ruffié, P; Terrier, P, 2010) |
| "Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single-agent ifosfamide and cisplatin with etoposide." | 9.09 | Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. ( Aisner, J; Aisner, S; Green, M; Jiroutek, M; Johnson, DH; Livingston, R; Loehrer, PJ; Thomas, CR, 2001) |
| "To evaluate single-agent ifosfamide in the treatment of invasive thymoma." | 7.70 | Treatment of invasive thymoma with single-agent ifosfamide. ( Bryant, B; Dussek, J; Harper, PG; Highley, MS; Hodson, N; Hughes, J; Karapetis, C; Parnis, FX; Rankin, E; Rowland, C; Underhill, CR, 1999) |
| "From October 1995 to April 2001, 18 patients with advanced thymoma or thymic carcinoma were entered on trial, and receive etoposide (100 mg/m(2) on days 1-3), ifosfamide (1500 mg/m(2) on days 1-3), s and cisplatin (30 mg/m(2) on days 1-3)." | 5.14 | Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. ( André, M; Bretel, JJ; Caliandro, R; Grassin, F; Le Chevalier, T; Margery, J; Paleiron, N; Ruffié, P; Terrier, P, 2010) |
| "Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single-agent ifosfamide and cisplatin with etoposide." | 5.09 | Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. ( Aisner, J; Aisner, S; Green, M; Jiroutek, M; Johnson, DH; Livingston, R; Loehrer, PJ; Thomas, CR, 2001) |
| " There are little data concerning the activity of ifosfamide in thymoma and further investigation of the role of this drug in combination chemotherapy regimens, particularly as an alternative to the inclusion of cyclophosphamide, is warranted." | 4.82 | Ifosfamide in thymic neoplasms. ( Daniele, O; Fornasiero, A, 2003) |
| "To evaluate single-agent ifosfamide in the treatment of invasive thymoma." | 3.70 | Treatment of invasive thymoma with single-agent ifosfamide. ( Bryant, B; Dussek, J; Harper, PG; Highley, MS; Hodson, N; Hughes, J; Karapetis, C; Parnis, FX; Rankin, E; Rowland, C; Underhill, CR, 1999) |
| "Thymomas are the most common tumours of the anterior mediastinum; their clinical course is often complicated by accompanying autoimmune and paraneoplastic syndromes." | 2.47 | The role of somatostatin analogues in the treatment of advanced malignant thymomas: case report and review of the literature. ( El-Modir, A; Pettit, L, 2011) |
| "Thymomas and thymic carcinomas are unique tumors of the anterior mediastinum." | 2.41 | Thymic malignancies. ( Loehrer, PJ; Wick, MR, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, SY | 1 |
| Xie, L | 1 |
| Liu, ET | 1 |
| Liao, JQ | 1 |
| Chen, G | 1 |
| Wang, SX | 1 |
| Grassin, F | 1 |
| Paleiron, N | 1 |
| André, M | 1 |
| Caliandro, R | 1 |
| Bretel, JJ | 1 |
| Terrier, P | 1 |
| Margery, J | 2 |
| Le Chevalier, T | 1 |
| Ruffié, P | 1 |
| Pettit, L | 1 |
| El-Modir, A | 1 |
| Iwasaki, Y | 2 |
| Ohsugi, S | 1 |
| Takemura, Y | 1 |
| Nagata, K | 1 |
| Harada, H | 1 |
| Nakagawa, M | 2 |
| Daniele, O | 2 |
| Fornasiero, A | 2 |
| Magois, E | 1 |
| Guigay, J | 1 |
| Blancard, PS | 1 |
| Milleron, B | 1 |
| Lher, P | 1 |
| Jounieaux, V | 1 |
| Niehues, T | 1 |
| Harms, D | 1 |
| Jürgens, H | 1 |
| Göbel, U | 1 |
| Kubota, Y | 1 |
| Yokomura, I | 1 |
| Ueda, M | 1 |
| Hashimoto, S | 1 |
| Arimoto, T | 1 |
| Inaba, T | 1 |
| Shimazaki, C | 1 |
| Toda, S | 1 |
| Highley, MS | 1 |
| Underhill, CR | 1 |
| Parnis, FX | 1 |
| Karapetis, C | 1 |
| Rankin, E | 1 |
| Dussek, J | 1 |
| Bryant, B | 1 |
| Rowland, C | 1 |
| Hodson, N | 1 |
| Hughes, J | 1 |
| Harper, PG | 1 |
| Loehrer, PJ | 2 |
| Wick, MR | 1 |
| Jiroutek, M | 1 |
| Aisner, S | 1 |
| Aisner, J | 1 |
| Green, M | 1 |
| Thomas, CR | 1 |
| Livingston, R | 1 |
| Johnson, DH | 1 |
| Ghiotto, C | 1 |
| Piazza, M | 1 |
| Fiore-Donati, L | 1 |
| Calabró, F | 1 |
| Rea, F | 1 |
| Fiorentino, MV | 1 |
4 reviews available for ifosfamide and Carcinoma, Thymic
| Article | Year |
|---|---|
The role of somatostatin analogues in the treatment of advanced malignant thymomas: case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; E | 2011 |
Ifosfamide in thymic neoplasms.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials a | 2003 |
Treatment of pediatric malignant thymoma: long-term remission in a 14-year-old boy with EBV-associated thymic carcinoma by aggressive, combined modality treatment.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytoge | 1996 |
Thymic malignancies.
Topics: Adrenal Cortex Hormones; Agammaglobulinemia; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2001 |
3 trials available for ifosfamide and Carcinoma, Thymic
| Article | Year |
|---|---|
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; I | 2010 |
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; I | 2001 |
Chemotherapy for invasive thymoma. A 13-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 1991 |
5 other studies available for ifosfamide and Carcinoma, Thymic
| Article | Year |
|---|---|
FDG-PET/CT of invasive thymoma extending into the superior vena cava and right atrium.
Topics: Aged; Cisplatin; Fluorodeoxyglucose F18; Heart Atria; Humans; Ifosfamide; Male; Neoplasm Metastasis; | 2019 |
Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood stem cell transplantation for invasive thymoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2002 |
Multimodal treatment of thymic carcinoma: Report of nine cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; E | 2008 |
[Invasive thymoma successfully treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation(PBSCT)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality The | 1998 |
Treatment of invasive thymoma with single-agent ifosfamide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Male; Middle Aged; Neopl | 1999 |